Melinta Therapeutics, LLC
Parsippany-Troy Hills, NJ Part of Cormedix Inc.
- UEI
- H8K6F2A4KD49
- CAGE
- 7XFT1
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- Corporate family
-
-
Parent
Berkeley Heights, NJ
K6BBWLG82PM3
-
- ELLHEBHB4ZQ7
- J7VXX495LZS5
-
-
Parent
Berkeley Heights, NJ
K6BBWLG82PM3
- SAM.gov registration date
- Physical address
- 389 Interpace Pkwy #450, Parsippany-Troy Hills, NJ 07054, USA
- Website
- cormedix.com
- Founded
- 2006
- Employees
- 11-50
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $21,335,789 |
| FY2024 | $5,662,702 |
| FY2023 | $20,522,756 |
Contract vehicles
Contract awards
Similar vendors
About the company
Melinta Therapeutics, LLC, doing business as Melinta Therapeutics, is a for-profit limited liability company and manufacturer of goods registered to receive awards from the U.S. federal government. The company specializes in the development and production of antibiotics and pharmaceutical products, particularly those targeting serious bacterial infections and multidrug-resistant organisms. Melinta Therapeutics has been actively engaged in federal contracting since at least March 2018, when it first registered in SAM.gov. The company's expertise in antibiotic development positions it as a valuable partner for government agencies seeking to address public health concerns and biothreat emergencies.
The company's most significant recent federal contract award came from the Office of the Assistant Secretary for Preparedness and Response, a civilian agency. This $142,964,968.00 definitive cost-sharing contract, awarded on July 6, 2023, focuses on advancing the development of two antibiotics for use in the pediatric population to treat serious bacterial infections where multidrug-resistant organisms are common. Additionally, the contract supports the development of antibiotics for use in public health and biothreat emergencies. This substantial award, set to run until August 6, 2034, underscores Melinta Therapeutics' critical role in addressing urgent medical needs and strengthening national preparedness against potential biological threats.
Melinta Therapeutics holds several federal contract Indefinite Delivery Vehicles (IDVs), demonstrating its ongoing relationship with various government agencies. The company has a Federal Supply Schedule contract (36F79724D0178) awarded by the Department of Veterans Affairs, with a ceiling value of $9,658,300.00, for providing pharmaceutical, drug, and hematology-related products under category 65 IB. This multiple-award contract allows other federal agencies to procure these products through August 31, 2029. Additionally, Melinta has two Blanket Purchase Agreements (BPAs) with the National Acquisition Center, both for a product called REZZAYO. One BPA (36F79724D0178|36E79724A0033) has a ceiling value of $7,295.85 and runs until September 19, 2025, while the other (36F79718D0456|36E79724A0014) has a ceiling of $500,000.00 and is effective through August 31, 2024. The latter BPA is established under the GSA Pharmaceutical and Drugs (FSS-61-IB) schedule, indicating Melinta's ability to provide pharmaceutical products to various federal healthcare systems efficiently.
Quick answers
Is Melinta Therapeutics, LLC registered in SAM.gov?
Yes. Melinta Therapeutics, LLC's SAM.gov registration is active through September 9, 2027.
What is Melinta Therapeutics, LLC's CAGE code?
Melinta Therapeutics, LLC's CAGE code is 7XFT1, and its Unique Entity ID (UEI) is H8K6F2A4KD49.
Which contract vehicles does Melinta Therapeutics, LLC hold?
Melinta Therapeutics, LLC holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Melinta Therapeutics, LLC received in federal contracts?
Federal contracts obligated $21,335,789 to Melinta Therapeutics, LLC in fiscal year 2025 and $47,521,247 in fiscal years 2023 through 2027.
How does Melinta Therapeutics, LLC rank among federal contractors?
Melinta Therapeutics, LLC ranked #19 in NAICS 541714 and #33 in PSC AN in FY2025.
What is Melinta Therapeutics, LLC's most recent federal award?
Melinta Therapeutics, LLC's most recent federal contract award is Advance the development of two antibiotics for use in the pediatric population for the treatment of serious bacterial… (75A50123C00022), from Office of the Assistant Secretary for Preparedness and Response, on July 6, 2023.
On GovTribe
See Melinta Therapeutics, LLC's full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors